Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-337-4701
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees102
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions
What is Neon Therapeutics' stock symbol?
Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."
How were Neon Therapeutics' earnings last quarter?
Neon Therapeutics Inc (NASDAQ:NTGN) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.01. View Neon Therapeutics' Earnings History.
When is Neon Therapeutics' next earnings date?
What price target have analysts set for NTGN?
5 brokers have issued 1-year price objectives for Neon Therapeutics' stock. Their forecasts range from $12.00 to $21.00. On average, they expect Neon Therapeutics' share price to reach $15.20 in the next twelve months. This suggests a possible upside of 691.7% from the stock's current price. View Analyst Price Targets for Neon Therapeutics.
What is the consensus analysts' recommendation for Neon Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neon Therapeutics.
What are Wall Street analysts saying about Neon Therapeutics stock?
Here are some recent quotes from research analysts about Neon Therapeutics stock:
- 1. According to Zacks Investment Research, "Neon Therapeutics Inc. is a clinical-stage immuno-oncology company. It engaged in developing neoantigen-based therapeutics for the treatment of cancer by directing the immune system. The company's product pipeline consists of NEO-PV-01, NEO-PTC-01 and NEO-SV-01 which are in clinical stage. Neon Therapeutics Inc. is based in Cambridge, United States. " (10/12/2019)
- 2. HC Wainwright analysts commented, "Our assessment is driven by a discounted cash flow (DCF)-based approach, which utilizes a 10% discount rate, 1.0% terminal growth rate, and 30% probability of approval for NEO-PV-01 in front-line melanoma, NSCLC, and bladder cancer. We assume a 29% effective tax rate." (9/16/2019)
Has Neon Therapeutics been receiving favorable news coverage?
Media stories about NTGN stock have been trending negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neon Therapeutics earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Neon Therapeutics.
Are investors shorting Neon Therapeutics?
Neon Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totalling 1,030,000 shares, an increase of 47.7% from the August 15th total of 697,200 shares. Based on an average daily trading volume, of 583,100 shares, the short-interest ratio is currently 1.8 days. Currently, 7.1% of the company's shares are short sold. View Neon Therapeutics' Current Options Chain.
Who are some of Neon Therapeutics' key competitors?
Some companies that are related to Neon Therapeutics include Dyadic International (DYAI), Oncobiologics (ONS), X4 Pharmaceuticals (XFOR), Acorda Therapeutics (ACOR), Axcella Health (AXLA), Nantkwest (NK), Adaptimmune Therapeutics (ADAP), Windtree Therapeutics (WINT), Aptose Biosciences (APTO), Jounce Therapeutics (JNCE), Novavax (NVAX), Allena Pharmaceuticals (ALNA), Gamida Cell (GMDA), Vical (VICL) and Brainstorm Cell Therapeutics (BCLI).
What other stocks do shareholders of Neon Therapeutics own?
Who are Neon Therapeutics' key executives?
Neon Therapeutics' management team includes the folowing people:
- Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)
- Dr. Eric S. Lander, Founder & Director (Age 62)
- Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)
- Dr. Richard Gaynor, Pres of R&D (Age 69)
- Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer
When did Neon Therapeutics IPO?
(NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager.
How do I buy shares of Neon Therapeutics?
Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neon Therapeutics' stock price today?
One share of NTGN stock can currently be purchased for approximately $1.92.
How big of a company is Neon Therapeutics?
Neon Therapeutics has a market capitalization of $54.49 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.View Additional Information About Neon Therapeutics.
What is Neon Therapeutics' official website?
How can I contact Neon Therapeutics?
Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]
MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)
MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
